ICI-IO Combinations Summit 2019 is organized by Hanson Wade and will be held from Mar 19 - 21, 2019 at The Colonnade Boston Hotel, Boston, Massachusetts, United States of America.
Advancing ICI-containing IO-combination therapies is central to getting the full therapeutic benefit out of ICIs. Selecting the right combination partners and strategies are essential to making the correct decision.
This industry-led meeting will focus on how the response rate to checkpoint combinations can be enhanced to impact every stage of the cancer immunity cycle, as well as shed light on the specific challenges that come with combining IO therapies with ICIs.
Through interactive workshops, panel discussions and roundtables, this is a great opportunity to gain practical implementable insight into IO combo development strategy.
At the heart of these challenges, there is a mechanistic understanding of the body’s immune-based anti-tumor responses. The ICI-IO Combinations Summit focuses exclusively on how to leverage this integrated system to deliver maximum clinical benefit, through the combinations of immune checkpoint modulators with immuno-oncology therapies.
The meeting will deliver granular insights on the preclinical, translational and clinical challenges that drug developers face when seeking out combination partners for their ICI drugs. Rather than a general overview of the IO space, a combination of case-study based stories of successes and failures partnered with insight-led discussion will you with providing solutions to intricate IO challenges.
Pre-Clinical Development Challenges in Checkpoint Modulators and IO Combinations will be held on Mar 19, 2019.
This workshop will give you the practical skills and insight to help you make informed decisions at the preclinical phase, leading you to more robust and reliable results at the trial stage. Through
case studies and group discussions, this interactive session will dive into the following areas, which prime your preclinical understanding prior to the main conference:
Topics that are being covered include:
• A breakdown of the models that are currently available, their relative translatability and where they can be implemented best for both ICIs and IO combinations.
• An analysis of the key challenges that are being faced at the preclinical stage and the key developments that will enable us to overcome them.
• Look at how you can build a robust scientific rationale at the preclinical stage to drive greater success at the clinical phase.
Speakers: Sarah McWhirter Aduro Biotech, Jeremy Graff Biothera, Jochem Gokelmeijer Bristol-Myers Squibb, Mark Paris Director Mitra Biotech, Mithun Khattar Takeda, Osama Rahma Dana-Faber Cancer Center, Patrick Holder Genentech, Paul Moore Macrogenics, Raphael Clynes Xencor, Shanthi Ganesh Pharmaceuticals, Stephen Doberstein Nektar Therapeutics, Viviana Cremasco Novartis, Weiyi Peng MD Anderson Cancer Center, Wim Van Schooten Teneobio, John Burke Applied Biomath, Paul Rennert Aleta Biotherapeutics, Mark Yore Jounce Therapeutics, Amy-Jo Casbon Amgen Inc., Bei Wang Regeneron, Beth Trehu Jounce Therapeutics, Bruno Osterwalder BO Consulting, Catherine Sabatos-Peyton Novartis, Cedric Dos Santos Amgen Inc., Eva Vanamee FusionBio, Hans Van Eenemann Aduro Biotech
Time: 9:00 am to 5:00 pm
|Contact No.||:||+1 617 455 4188|
|Registration Type||End Date||Price|
|Conference Plus 1 Workshop (Industry) Early Fee||18 Jan,2019||USD 3198.00|
|Conference Plus 1 Workshop (Industry) Standard Fee||18 Mar,2019||USD 3498.00|
|Conference Only (Industry) Early Fee||18 Jan,2019||USD 2699.00|
|Conference Only (Industry) Standard Fee||18 Mar,2019||USD 2899.00|
|Workshops (Each) (Industry) Fee||18 Mar,2019||USD 699.00|
|Conference Plus 1 Workshop (Small Biotech) Early Fee||18 Jan,2019||USD 1998.00|
|Conference Plus 1 Workshop (Small Biotech) Standard Fee||18 Mar,2019||USD 2198.00|
|Conference Only (Small Biotech) Early Fee||18 Jan,2019||USD 1699.00|
|Conference Only (Small Biotech) Standard Fee||18 Mar,2019||USD 1899.00|
|Workshops (Each) (Small Biotech) Fee||18 Mar,2019||USD 399.00|